SEER Inquiry System - View

Question: 20130221 Status
Final

References
Source 1:   2007 MP/H Rules
pgs:  
Notes:  
Source 2:  
pgs:  
Notes:  


Question
MP/H Rules/Multiple Primaries--Prostate: Is a metastatic small cell (neuroendocrine) carcinoma following a prostate adenocarcinoma a new primary when the physician states “patient has Stage 4 small cell carcinoma of the prostate” or “metastatic small cell carcinoma, likely prostate origin”? See discussion.

Discussion
Would a second prostate primary with histology 8041 be reported or is this metastasis from the previous prostate adenocarcinoma diagnosis, despite the different histologies?

Examples –
1. Prostate adenocarcinoma diagnosed in 2001, no treatment given. Metastatic small cell neuroendocrine carcinoma diagnosed 03/2012 on liver biopsy with physician’s statement in 4/2012 that prostate is the likely the cause of the metastasis to the liver.
2. Prostate adenocarcinoma diagnosed in 2006, treated with TURP. Bone Marrow biopsy in 05/2012 shows involvement by metastatic small cell carcinoma with morphologic and immunophenotypic features that argue against prostatic adenocarcinoma. Oncologist assessment states “the patient has Stage 4 small cell carcinoma of the prostate and the bone marrow biopsy path shows metastatic small cell carcinoma (likely prostate in origin)”.

Answer
Rule M10 applies to the case examples you provide. In each case, the second histology (since it is not adenocarcinoma) is a new prostate primary. Small cell carcinoma and small cell neuroendocrine carcinoma are not adenocarcinomas and are not covered by Rule M3.

History


Last Updated
12/12/2013

Date Finalized
02/05/2014